Seeking Alpha

Oncolytics Biotech® Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care

Pelareorep plus atezolizumab achieves 30% ORR in second-line or later (≥2L) squamous cell anal carcinoma (SCAC) relative to 13.8% for the FDA-approved 2L treatment The median duration of response was ...
Seeking Alpha

Oncolytics Biotech® Reports Interim Results from Phase 1/2 GOBLET Study Showing a 70% Objective Response Rate in Pancreatic Cancer at the SITC Annual Meeting

70% objective response rate (ORR; n=10) is nearly triple the average ORR of ~25% reported in historical control trials 1-4 Data suggest pelareorep synergizes with PD-(L)1 inhibitors and ...
MarketWatch

Oncolytics Biotech(R) Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care

The MarketWatch News Department was not involved in the creation of this content. Pelareorep plus atezolizumab achieves 30% ORR in second-line or later (>=2L) squamous cell anal carcinoma (SCAC) ...